Doctors Without Borders/Médecins Sans Frontières (MSF) applauds today’s news that the Indian Patent Office rejected the US pharmaceutical corporation Johnson & Johnson’s (J&J) attempt to extend its monopoly in India on the tuberculosis (TB) drug bedaquiline beyond when its primary patent expires in July. The rejection is a significant step toward increasing access to the lifesaving TB drug. Read more here.
top of page
bottom of page